Bendamustine-d8 (hydrochloride)

Bendamustine-d8 (hydrochloride)

• CAS Number: 1185068-23-8
• UNSPSC Description: Bendamustine-d8 (hydrochloride) is deuterium labeled Bendamustine (hydrochloride). Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].
• Target Antigen: Apoptosis; DNA Alkylator/Crosslinker; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Others
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: O=C(O)CCCC1=NC2=CC(N(C([2H])([2H])C([2H])(Cl)[2H])C([2H])([2H])C([2H])(Cl)[2H])=CC=C2N1C.Cl
• Molecular Weight: 402.77
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91.|[3]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17.|[4]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported